Literature DB >> 29721603

Pneumatosis Intestinalis Associated with the Tyrosine Kinase Inhibitor Nintedanib.

Armeen Poor1, Sidney S Braman2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29721603     DOI： 10.1007/s00408-018-0118-6

Source DB:  PubMed          Journal:  Lung        ISSN： 0341-2040            Impact factor:   2.584


× No keyword cloud information.
  7 in total

1.  A review of pneumatosis intestinalis in the setting of systemic cancer treatments, including tyrosine kinase inhibitors.

Authors:  Niranjan Vijayakanthan; Kavita Dhamanaskar; Lori Stewart; Jodie Connolly; Brian Leber; Irwin Walker; Michael Trus
Journal:  Can Assoc Radiol J       Date:  2012-03-07       Impact factor: 2.248

2.  An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline.

Authors:  Ganesh Raghu; Bram Rochwerg; Yuan Zhang; Carlos A Cuello Garcia; Arata Azuma; Juergen Behr; Jan L Brozek; Harold R Collard; William Cunningham; Sakae Homma; Takeshi Johkoh; Fernando J Martinez; Jeffrey Myers; Shandra L Protzko; Luca Richeldi; David Rind; Moisés Selman; Arthur Theodore; Athol U Wells; Henk Hoogsteden; Holger J Schünemann
Journal:  Am J Respir Crit Care Med       Date:  2015-07-15       Impact factor: 21.405

3.  Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib.

Authors:  Romain Coriat; Stanislas Ropert; Olivier Mir; Bertrand Billemont; Stanislas Chaussade; Pierre-Philippe Massault; Benoit Blanchet; Olivier Vignaux; François Goldwasser
Journal:  Invest New Drugs       Date:  2010-06-05       Impact factor: 3.850

Review 4.  Pneumatosis cystoides intestinalis in systemic lupus erythematosus with intestinal vasculitis: treatment with high dose prednisone.

Authors:  G E Cabrera; E Scopelitis; M L Cuellar; L H Silveira; H Mena; L R Espinoza
Journal:  Clin Rheumatol       Date:  1994-06       Impact factor: 2.980

Review 5.  Pneumatosis intestinalis: a review.

Authors:  Y Heng; M D Schuffler; R C Haggitt; C A Rohrmann
Journal:  Am J Gastroenterol       Date:  1995-10       Impact factor: 10.864

6.  Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.

Authors:  Luca Richeldi; Roland M du Bois; Ganesh Raghu; Arata Azuma; Kevin K Brown; Ulrich Costabel; Vincent Cottin; Kevin R Flaherty; David M Hansell; Yoshikazu Inoue; Dong Soon Kim; Martin Kolb; Andrew G Nicholson; Paul W Noble; Moisés Selman; Hiroyuki Taniguchi; Michèle Brun; Florence Le Maulf; Mannaïg Girard; Susanne Stowasser; Rozsa Schlenker-Herceg; Bernd Disse; Harold R Collard
Journal:  N Engl J Med       Date:  2014-05-18       Impact factor: 91.245

7.  Pneumatosis intestinalis and portal venous gas secondary to Gefitinib therapy for lung adenocarcinoma.

Authors:  Joo Young Lee; Hye-Suk Han; Sung-Nam Lim; Young Kwang Shim; Yong Hyeok Choi; Ok-Jun Lee; Ki Hyeong Lee; Seung Taik Kim
Journal:  BMC Cancer       Date:  2012-03-10       Impact factor: 4.430
  7 in total
  1 in total

1.  Pneumatosis Intestinalis in the Setting of COVID-19: A Single Center Case Series From New York.

Authors:  Santiago J Miyara; Lance B Becker; Sara Guevara; Claudia Kirsch; Christine N Metz; Muhammad Shoaib; Elliot Grodstein; Vinay V Nair; Nicholas Jandovitz; Alexia McCann-Molmenti; Kei Hayashida; Ryosuke Takegawa; Koichiro Shinozaki; Tsukasa Yagi; Tomoaki Aoki; Mitsuaki Nishikimi; Rishabh C Choudhary; Young Min Cho; Stavros Zanos; Stefanos Zafeiropoulos; Hannah B Hoffman; Stacey Watt; Claudio M Lumermann; Judith Aronsohn; Linda Shore-Lesserson; Ernesto P Molmenti
Journal:  Front Med (Lausanne)       Date:  2021-06-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.